Back
 JCT  Vol.1 No.1 , March 2010
Transfusion of Ipscs-Derived Leukocytes to Kill Cancer
Abstract: Here we propose that the rejuvenation of leukocytes with iPSC technology in vitro and transfusion of cancer cellresistant white blood cells back to human body provide a prospective therapy for cancer patients.
Keywords: Ipscs, Leukocytes, Cancer
Cite this paper: nullJ. Li, Y. Cui, G. Gao and T. Yuan, "Transfusion of Ipscs-Derived Leukocytes to Kill Cancer," Journal of Cancer Therapy, Vol. 1 No. 1, 2010, pp. 29-30. doi: 10.4236/jct.2010.11004.
References

[1]   A. E. Moore, C. P. Rhoads, and C. M. Southam, “Homotransplantation of human cell lines,” Science, Vol. 125, No. 3239, pp. 158–160, 1957.

[2]   J. M. Pawelek and A. K. Chakraborty, “The cancer cell-leukocyte fusion theory of metastasis,” Advances in Cancer Research, Vol. 101, pp. 397–444. 2008.

[3]   A. M. Hicks, G. Riedlinger, M. C. Willingham, M. A. Alexander-Miller, C. Von Kap-Herr, M. J. Pettenati, A. M. Sanders, H. M. Weir, W. Du, J. Kim, et al., “Transferable anticancer innate immunity in spontaneous regression/complete resistance mice,” Proceedings of the National Academy of Science, USA, Vol. 103, No. 20, pp. 7753–7758, 2006.

[4]   J. Yu, M. A. Vodyanik, K. Smuga-Otto, J. Antosiewicz-Bourget, J. L. Frane, S. Tian, J. Nie, G. A. Jonsdottir, V. Ruotti, R. Stewart, et al., “Induced pluripotent stem cell lines derived from human somatic cells,” Science, Vol. 318, No. 5858, pp. 1917–1920, 2007.

[5]   K. Takahashi, K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda, and S. Yamanaka, “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” Cell, Vol. 131, No. 5, pp. 861–872, 2007.

[6]   G. Amabile and A. Meissner, “Induced pluripotent stem cells: Current progress and potential for regenerative medicine,” Trends in Molecular Medicine, Vol. 15, No. 2, pp. 59–68, 2009.

[7]   D. Kim, C. H. Kim, J. I. Moon, Y. G. Chung, M. Y. Chang, B. S. Han, S. Ko, E. Yang, K. Y. Cha, R. Lanza, et al., “Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins,” Cell Stem Cell, Vol. 4, No. 6, pp. 472–476, 2009.

[8]   H. Zhou, S. Wu, J. Y. Joo, S. Zhu, D. W. Han, T. Lin, S. Trauger, G. Bien, S. Yao, Y. Zhu, et al., “Generation of induced pluripotent stem cells using recombinant proteins,” Cell Stem Cell, Vol. 4, No. 5, pp. 381–384, 2009.

[9]   T. Lin, R. Ambasudhan, X. Yuan, W. Li, S. Hilcove, R. Abujarour, X. Lin, H. S. Hahm, E. Hao, A. Hayek, et al., “A chemical platform for improved induction of human iPSCs,” Nature Methods, Vol. 6, No. 11, pp. 805–808, 2009.

[10]   Y. Shi, Y. ZHao, and H. Deng, “Powering reprogramming with vitamin C,” Cell Stem Cell, Vol. 6, pp.1–2, 2010.

[11]   M. A. Esteban, T. Wang, B. Qin, J. Yang, D. Qin, J. Cai, W. Li, Z. Weng, J. Chen, S. Ni, et al., “Vitamin C Enhances the Generation of Mouse and Human Induced Pluripotent Stem Cells,” Cell Stem Cell, 2009.

[12]   J. M. Pawelek and A. K. Chakraborty, “Fusion of tumour cells with bone marrow-derived cells: A unifying explanation for metastasis,” Nature Reviews Cancer, Vol. 8, No. 5, pp. 377–386, 2008.

[13]   Z. G. Fridlender, J. Sun, S. Kim, V. Kapoor, G. Cheng, L. Ling, G. S. Worthen, and S. M. Albelda, “Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus "N2" TAN,” Cancer Cell, Vol. 16, No. 3, pp. 183–194, 2009.

[14]   M. Hannig, H. R. Figulla, H. Sauer, and M. Wartenberg, “Control of leukocyte differentiation from embryonic stem cells upon vasculogenesis and confrontation with tumour tissue,” Journal of Cellular and Molecular Medicine, 2008.

 
 
Top